Phase 1/1b Multicenter Open-Label Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors

Go Back to All Clinical Trials

Phase 1/1b Multicenter Open-Label Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors

Brief description of study

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors

Clinical Study Identifier: s24-00119

ClinicalTrials.gov Identifier: NCT06040541

Principal Investigator: Paul E. Oberstein.

Other Investigators: Marta Wioleta Wronska, Elaine Shum, David Mendoza, Vamsidhar Velcheti, Shun Yu, Joshua K Sabari, Jessica Wang, Danny Perlaza, Keriann M Scavone, Marissa Rybstein, Natalia Cherkassky, Nina Beri, Avital Benson, Salman Rafi Punekar, Sally Lau, Jeffrey G Schneider, Jennifer Chuy, Samantha VanMaanen, Daniel J Becker, Kristen Spencer, James Newman, Melissa L Martinez, Michael Shusterman, Rafael Winograd, Alexander A Hindenburg.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies